Researchers at UCL’s Institute for Immunity and Transplantation will investigate the power of regulatory T cells (blue) to help prevent disease and improve the success of transplants.
The projects, announced today by the Chancellor, will focus on physical sciences, medical research, advanced materials, pharmaceutical manufacturing and advanced manufacturing. They will tackle global challenges like developing new treatments for cancer, or ensuring advanced materials can cope under harsh conditions, including extracting oil and gas reservoirs.
This is the latest round of projects from the £300 million UK Research Partnership Investment Fund (UKRPIF), bringing the total number of winners to 20. Successful universities have secured at least double that amount of investment from businesses or charities, together delivering more than £1 billion of new funding for research.
Minister for Universities and Science, David Willetts, said:
'The UK’s world-class universities are at the forefront of our economic recovery. It’s vital we do everything we can to encourage collaboration with the private sector and boost funding for research. These excellent projects will not only deliver new knowledge and applications for industry, but will accelerate growth and foster innovation between the research base and business, keeping the UK ahead in the global race.
'Our £300 million investment has secured over £855 million from business and charities - a total investment of £1.15 billion. This is an extraordinary result, far exceeding the required private to public funding ratio of two to one.'
Sir Alan Langlands, Chief Executive of HEFCE, said:
'These five projects highlight yet again the success that UK universities have in working with commercial partners and charities to raise funds and deliver vital initiatives to stimulate research in critical areas vital to the economy. In challenging times, the higher education sector consistently demonstrates its key role in delivering growth.'
The five projects, representing £72 million of public support and attracting £219 million of additional private investment, are:
- A £33 million partnership between UCL (University College London) and the Royal Free London NHS Foundation Trust in the Institute of Immunity and Transplantation. This will enable world-leading research and clinical trials to develop new treatments and patient therapies for a range of chronic diseases, such as cancer, HIV and diabetes.
- A £117 million partnership between the University of Manchester, BP plc, Rolls-Royce, AMEC, Sellafield, National Nuclear Laboratory, FEI Company, Xradia, Rapiscan Systems, AREVA, Westinghouse, EDF and TiSiC to establish the Multidisciplinary Characterisation Facility. This will accelerate research into advanced materials that can operate safely under increasingly harsh conditions, such as the extraction of difficult to access oil and gas reservoirs or aero engines operating at higher temperatures.
- A £63 million partnership between the University of Cambridge, the Winton Programme for the Physics of Sustainability, Hitachi Ltd, the Herchel Smith Trust Fund and others to build The Maxwell Centre. This will be a centrepiece for industrial partnership in the physical sciences on the West Cambridge Science and Technology campus, increasing collaboration with SMEs and acting as a hub for doctoral training.
- A £34 million partnership between the University of Strathclyde, GlaxoSmithKline, AstraZeneca, Novartis, Cancer Research UK and others. It will build on the EPSRC Centre for Continuous Manufacturing and Crystallisation, a world-class facility to accelerate innovative technology delivery and establish new supply chains for medicines.
- A £43 million partnership between the University of Sheffield's Advanced Manufacturing Research Centre (AMRC) and manufacturing companies to develop the AMRC Factory 2050. This will be the world's most flexible factory, capable of rapidly switching production between different high-value components and one-off parts. It will support innovation in advanced manufacturing and meet the future needs of the market by integrating research and industry collaboration.
UKRPIF is managed by the Higher Education Funding Council for England (HEFCE), in collaboration with the other UK higher education funding bodies, with proposals assessed by an independent assessment panel. It was first launched with £100 million of public finance in May 2012 and in response to the large number of high-quality bids, the Government tripled the public support to £300 million in autumn 2012.
- HEFCE has allocated additional funding to support six projects from the latest round - bringing the total number of projects to 20 and the final commitment to £301.4 million levering £855 million from business and charities and total investment of £1.156 billion.
- The first of six projects from the latest round of UKRPIF, a £30 million medical science research centre at the University of Oxford, was announced by the Prime Minister on 3 May.
- The UKRPIF was set up in 2012. Details of the UKRPIF are available on the HEFCE web-site.
- The first set of seven UKRPIF projects was announced by BIS and the Treasury on 8 October 2012. The second set of seven projects was announced by BIS on 1 November 2012. These involve institutions across the whole of the UK.